1. Home
  2. ATYR vs CBAT Comparison

ATYR vs CBAT Comparison

Compare ATYR & CBAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • CBAT
  • Stock Information
  • Founded
  • ATYR 2005
  • CBAT 1999
  • Country
  • ATYR United States
  • CBAT China
  • Employees
  • ATYR N/A
  • CBAT N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • CBAT Industrial Machinery/Components
  • Sector
  • ATYR Health Care
  • CBAT Miscellaneous
  • Exchange
  • ATYR Nasdaq
  • CBAT Nasdaq
  • Market Cap
  • ATYR 77.1M
  • CBAT 90.4M
  • IPO Year
  • ATYR 2015
  • CBAT N/A
  • Fundamental
  • Price
  • ATYR $0.71
  • CBAT $0.87
  • Analyst Decision
  • ATYR Buy
  • CBAT
  • Analyst Count
  • ATYR 6
  • CBAT 0
  • Target Price
  • ATYR $8.75
  • CBAT N/A
  • AVG Volume (30 Days)
  • ATYR 3.8M
  • CBAT 190.3K
  • Earning Date
  • ATYR 11-06-2025
  • CBAT 11-10-2025
  • Dividend Yield
  • ATYR N/A
  • CBAT N/A
  • EPS Growth
  • ATYR N/A
  • CBAT N/A
  • EPS
  • ATYR N/A
  • CBAT N/A
  • Revenue
  • ATYR $190,000.00
  • CBAT $161,757,685.00
  • Revenue This Year
  • ATYR $420.85
  • CBAT N/A
  • Revenue Next Year
  • ATYR $1,513.40
  • CBAT $60.02
  • P/E Ratio
  • ATYR N/A
  • CBAT N/A
  • Revenue Growth
  • ATYR N/A
  • CBAT N/A
  • 52 Week Low
  • ATYR $0.68
  • CBAT $0.57
  • 52 Week High
  • ATYR $7.29
  • CBAT $1.28
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 29.54
  • CBAT 43.14
  • Support Level
  • ATYR $0.68
  • CBAT $0.89
  • Resistance Level
  • ATYR $0.77
  • CBAT $0.95
  • Average True Range (ATR)
  • ATYR 0.06
  • CBAT 0.04
  • MACD
  • ATYR 0.03
  • CBAT -0.00
  • Stochastic Oscillator
  • ATYR 11.19
  • CBAT 25.73

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About CBAT CBAK Energy Technology Inc.

CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.

Share on Social Networks: